FAQ Library

FAQ Library published on March 25, 2021
In this activity, Dr. Baljevic discusses the side-effect profile associated with four-drug regimens.
FAQ Library published on March 23, 2021
In this activity, Dr. Baljevic explains the NCCN guidelines outlining four-drug combinations listed for use in newly diagnosed transplant-eligible patients.
FAQ Library published on January 20, 2021
In this activity, Dr. Raje provides a summary of the KarMMa trial and BB2121 in relapsed/refractory multiple myeloma.
FAQ Library published on January 14, 2021
Dr. Raje explains therapeutic interventions for smoldering multiple myeloma, as well as how to better risk-stratify patients.
FAQ Library published on January 12, 2021
In this activity, Dr. Noopur Raje discusses how to risk-stratify patients with smoldering myeloma and the updated definition of symptomatic myeloma.
FAQ Library published on November 18, 2020
In this activity, Dr. Usmani describes RVD lite and where to utilize this regimen best in practice.
FAQ Library published on May 20, 2020
Join Dr. Lonial as he explains selecting treatment that may lessen immunosuppression amid the COVID-19 pandemic.
FAQ Library published on May 20, 2020
In this activity, Dr. Lonial explains how the COVID-19 pandemic is impacting clinical trial enrollment in multiple myeloma.
FAQ Library published on May 20, 2020
Join Dr. Lonial as he discusses how to continue treatment with your patients who are already immunocompromised during the COVID-19 pandemic.
FAQ Library published on May 20, 2020
In this activity, Dr. Lonial explains how the COVID-19 pandemic is impacting care delivery in his patients with multiple myeloma.
Page 1 of 16
Results 1 - 10 of 157